ZyVersa Therapeutics Explores Cost Cuts, Divestments, & 'Going Dark'

ZyVersa Therapeutics is exploring significant cost-cutting measures to conserve resources and raise capital, including potential divestment of product candidates, employee headcount reductions, and possibly "going dark" by suspending SEC reporting. CEO Stephen Glover and CFO Peter Wolfe have voluntarily accepted reduced compensation. Additionally, the company is considering broader strategic alternatives such as a sale of the company or its assets, or restructuring, to maximize shareholder value. This comes as Dr. Min Chul Park resigned from the Board of Directors for personal reasons.